Profile data is unavailable for this security.
About the company
Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
- Revenue in SEK (TTM)136.41m
- Net income in SEK-283.79m
- Incorporated--
- Employees127.00
- LocationCamurus ABSolvegatan 41LUND 223 62SwedenSWE
- Phone+46 462865730
- Fax+46 462865739
- Websitehttps://www.camurus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calliditas Therapeutics AB | 185.30m | -53.74m | 3.72bn | 17.00 | -- | 5.13 | -- | 20.07 | -1.19 | -1.19 | 4.89 | 18.72 | 0.2667 | -- | 9.32 | 13,235,930.00 | -7.74 | -- | -8.25 | -- | -- | -- | -29.00 | -- | -- | -- | 0.0032 | -- | -- | -- | 75.33 | -- | -- | -- |
| Oriola Oyj | 18.60bn | 117.80m | 3.97bn | 2.56k | 36.24 | 2.86 | 7.20 | 0.2136 | 0.0579 | 0.0579 | 9.83 | 0.7336 | 1.67 | 5.74 | 8.54 | 633,073.10 | 1.07 | 2.81 | 3.75 | 9.09 | 20.24 | 21.51 | 0.639 | 1.64 | 0.4469 | 4.38 | 0.6431 | 74.70 | 10.89 | 1.32 | -25.93 | -29.67 | -6.14 | -- |
| Orphazyme A/S | 0.00 | -471.89m | 4.05bn | 86.00 | -- | 40.37 | -- | -- | -16.87 | -16.87 | 0.00 | 2.65 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -47.70 | 0.5836 | -- | -- | -- | -46.99 | -- | -- | -- |
| Hansa Biopharma AB | 3.33m | -380.90m | 5.32bn | 78.00 | -- | 11.23 | -- | 1,597.68 | -9.52 | -9.52 | 0.0833 | 11.84 | 0.0046 | -- | 0.3484 | 45,027.03 | -52.99 | -38.19 | -57.02 | -41.55 | 73.35 | 85.18 | -11,431.57 | -4,954.36 | -- | -164.28 | 0.0193 | -- | 0.1787 | 15.76 | -45.18 | -- | 23.28 | -- |
| BioArctic AB | 254.82m | 78.39m | 5.67bn | 43.00 | 85.89 | 6.93 | 64.64 | 22.26 | 0.8965 | 0.8965 | 2.85 | 11.11 | 0.2074 | -- | -- | 6,067,024.00 | 6.38 | -- | 7.38 | -- | 88.25 | -- | 30.76 | -- | -- | -- | 0.0245 | -- | -60.53 | -- | -76.82 | -- | -- | -- |
| Camurus AB | 136.41m | -283.79m | 6.66bn | 127.00 | -- | 11.68 | -- | 48.83 | -5.73 | -5.73 | 2.74 | 11.05 | 0.1903 | 1.05 | 5.80 | 1,136,725.00 | -39.59 | -34.29 | -48.18 | -42.75 | 79.42 | 92.92 | -208.05 | -200.02 | 2.51 | -235.64 | 0.044 | -- | 114.12 | -12.70 | -23.52 | -- | 29.19 | -- |
| Oncopeptides AB | 0.00 | -903.96m | 8.05bn | 121.00 | -- | 14.34 | -- | -- | -16.75 | -16.75 | 0.00 | 9.13 | 0.00 | -- | -- | 0.00 | -125.14 | -109.07 | -148.75 | -137.31 | -- | -- | -- | -- | -- | -1,068.00 | 0.00 | -- | -- | -- | -80.17 | -- | -- | -- |
| Recipharm AB (publ) | 8.24bn | 33.40m | 8.71bn | 7.29k | 413.90 | 1.46 | 9.79 | 1.06 | 0.2638 | 0.2638 | 102.84 | 74.81 | 0.441 | 2.50 | 4.66 | 1,199,156.00 | 0.1793 | 1.52 | 0.2025 | 1.75 | 47.00 | 48.07 | 0.4066 | 2.77 | 1.50 | 2.22 | 0.7082 | 34.23 | 17.00 | 23.75 | 115.18 | 16.45 | 11.35 | -- |
| AddLife AB | 3.69bn | 159.60m | 9.25bn | 1.00k | 59.57 | 6.04 | 24.44 | 2.51 | 1.41 | 1.41 | 32.70 | 13.94 | 1.14 | 5.23 | 5.75 | 3,956,438.00 | 4.98 | -- | 8.51 | -- | 34.69 | -- | 4.37 | -- | 0.4932 | 13.33 | 0.4178 | -- | 40.21 | -- | 8.74 | -- | -- | -- |
Data as of Jun 03 2020. Currency figures normalised to Camurus AB's reporting currency: Swedish Krona SEK
19.47%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Max Mitteregger Kapitalf�rvaltning ABas of 30 Apr 2020 | 3.86m | 7.48% |
| Fj�rde AP-fondenas of 30 Apr 2020 | 3.33m | 6.45% |
| Catella Fondf�rvaltning ABas of 31 Dec 2019 | 1.06m | 2.05% |
| Enter Fonder ABas of 30 Apr 2020 | 437.56k | 0.85% |
| Handelsbanken Fonder ABas of 31 Mar 2020 | 404.95k | 0.78% |
| SEB Investment Management ABas of 30 Apr 2020 | 347.87k | 0.67% |
| Lancelot Asset Management ABas of 30 Apr 2020 | 328.00k | 0.64% |
| Andra AP-fondenas of 31 Dec 2019 | 180.86k | 0.35% |
| BlackRock Fund Advisorsas of 07 May 2020 | 77.44k | 0.15% |
| Vanguard Investments Australia Ltd.as of 31 Mar 2020 | 23.76k | 0.05% |
More ▼
Data from 31 Dec 2016 - 30 Apr 2020Source: FactSet Research Systems Inc.
